BACKGROUND: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. Vitamin D has been related to the prevention of MS and to modulating its course. Recent studies have shown the safety of high-dose vitamin D in MS. OBJECTIVE: This study compared the effects of high-dose vitamin D on interleukin 10 (IL-10) levels in MS patients in a double-blind, randomized clinical trial. METHODS:Ninety-four patients with relapsing remitting MS (RRMS) were randomized into a treatment and a placebo group. Both groups received conventional MS treatment. The intervention group received 50,000 IU of vitamin D every 5 days for 3 months. IL-10 was measured at baseline and after 3 months. RESULTS:Serum levels of IL-10 were (median ± IQR): 12.58 ± 11.97 and 10.97 ± 9.97 pg/ml in the intervention and placebo groups, respectively, at baseline (p = 0.161); after 3 months, these levels were 13.76 ± 18.95 and 11.31 ± 19.63 pg/ml, respectively (p = 0.158). The IL-10 level increased significantly after receiving high-dose vitamin D for 3 months (β = 0.737, p = 0.015 and R2 = 0.91). CONCLUSION:IL-10 levels increased significantly in RRMS patients after taking high-dose vitamin D3 for 3 months. High-dose vitamin D might be useful in promoting an anti-inflammatory state in RRMS patients.
RCT Entities:
BACKGROUND:Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. Vitamin D has been related to the prevention of MS and to modulating its course. Recent studies have shown the safety of high-dose vitamin D in MS. OBJECTIVE: This study compared the effects of high-dose vitamin D on interleukin 10 (IL-10) levels in MS patients in a double-blind, randomized clinical trial. METHODS: Ninety-four patients with relapsing remitting MS (RRMS) were randomized into a treatment and a placebo group. Both groups received conventional MS treatment. The intervention group received 50,000 IU of vitamin D every 5 days for 3 months. IL-10 was measured at baseline and after 3 months. RESULTS: Serum levels of IL-10 were (median ± IQR): 12.58 ± 11.97 and 10.97 ± 9.97 pg/ml in the intervention and placebo groups, respectively, at baseline (p = 0.161); after 3 months, these levels were 13.76 ± 18.95 and 11.31 ± 19.63 pg/ml, respectively (p = 0.158). The IL-10 level increased significantly after receiving high-dose vitamin D for 3 months (β = 0.737, p = 0.015 and R2 = 0.91). CONCLUSION:IL-10 levels increased significantly in RRMS patients after taking high-dose vitamin D3 for 3 months. High-dose vitamin D might be useful in promoting an anti-inflammatory state in RRMS patients.
Authors: Alexandra C Purdue-Smithe; Keewan Kim; Carrie Nobles; Enrique F Schisterman; Karen C Schliep; Neil J Perkins; Lindsey A Sjaarda; Joshua R Freeman; Sonia L Robinson; Jeannie G Radoc; James L Mills; Robert M Silver; Aijun Ye; Sunni L Mumford Journal: Nat Commun Date: 2021-05-13 Impact factor: 14.919
Authors: Prue H Hart; Robyn M Lucas; David R Booth; William M Carroll; David Nolan; Judith M Cole; Anderson P Jones; Allan G Kermode Journal: Front Immunol Date: 2017-01-24 Impact factor: 7.561
Authors: Vanitha A Jagannath; Graziella Filippini; Carlo Di Pietrantonj; G V Asokan; Edward W Robak; Liz Whamond; Sarah A Robinson Journal: Cochrane Database Syst Rev Date: 2018-09-24
Authors: Karen O'Connell; Jamal Sulaimani; Sharee A Basdeo; Katie Kinsella; Sinead Jordan; Orla Kenny; Siobhan B Kelly; David Murphy; Eric Heffernan; Ronan P Killeen; Keith Mulready; Marguerite MacMahon; Jennifer J Brady; Carmel McKenna; Ciaran Muldowney; Lorraine Cassidy; Cathal Walsh; Killian O'Rourke; Niall Tubridy; Chris McGuigan; Jean M Fletcher; Michael Hutchinson Journal: Mult Scler J Exp Transl Clin Date: 2017-09-21